Table 1.
Baseline characteristics.
| Parameter | Total Population (n = 19) |
|---|---|
| Demographics | |
| Male, n (%) | 18 (95) |
| Age, years | 65 ± 10 |
| Octogenarian, n (%) | 1 (5) |
| Ischemic etiology HF, n (%) | 12 (63) |
| Clinical characteristics | |
| BMI, kg/m2 | 23.4 ± 3.5 |
| Systolic BP, mmHg | 88 ± 13 |
| Diastolic BP, mmHg | 58 ± 9 |
| NYHA | 3.2 ± 0.7 |
| Co-morbidities | |
| PCI, n (%) | 10 (53) |
| CABG, n (%) | 3 (16) |
| Atrial fibrillation, n (%) | 11 (58) |
| Valve surgery, n (%) | 1 (5) |
| Diabetes, n (%) | 9 (47) |
| COPD, n (%) | 5 (26) |
| Baseline therapy | |
| ACE-I/ARB, n (%) | 14 (74) |
| Beta-blockers, n (%) | 9 (47) |
| MRA, n (%) | 13 (68) |
| Loop diuretic, n (%) | 14 (74) |
| Amiodarone, n (%) | 9 (47) |
| ICD or CRT-D, n (%) | 10 (53) |
| Heart failure | |
| LVEF (%) | 21 ± 5 |
| Destination therapy, n (%) | 12 (63) |
| Bridge to treatment, n (%) | 7 (37) |
| Dobutamine mean dose, γ/kg/min | 2.6 ± 1.2 |
BMI: body mass index, PCI: percutaneous coronary intervention, CABG: coronary artery bypass surgery, COPD: chronic obstructive pulmonary disease, ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blockers, MRA: mineralocorticoids receptor antagonists, ICD: implantable cardioverter defibrillator, CRT-D: cardiac resynchronization therapy defibrillator, LVEF: left ventricular ejection fraction.